Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure Drug's hidden effects revealed in new study

NCT ID NCT04498780

Knowledge-focused Sponsor: University of Leipzig Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug Sacubitril-Valsartan changes heart function in people with heart failure and reduced pumping ability. Researchers used a non-invasive method to measure heart pressure and volume in 117 participants. The goal is to uncover the mechanisms behind the drug's known benefits, such as fewer hospitalizations and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sacubitril-Valsartan
What this could lead to
If successful, this could help doctors understand why Sacubitril-Valsartan improves symptoms and survival in heart failure patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

117 people

The number who actually took part.

Started

Jul 2020

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with symptomatic heart failure (NYHA functional class II to IV) and reduced ejection fraction (LVEF≤40%) with clinical indication for therapy with Sacubitril-Valsartan

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic heart failure (NYHA functional class II to IV) * Reduced LV ejection fraction (≤ 40%) * Clinical indication for therapy with Sacubitril-Valsartan Exclusion Criteria: * catecholamine therapy at inclusion * existing therapy with Sacubitril-Valsartan * planned cardiac resynchronization therapy (CRT) within 6 months; inclusion at least 3 months after CRT * planned mitral or aortic valve procedure within 6 months; inclusion at least 3 months after valve procedure * participation in another randomized heart failure trial * severe aortic or mitral valve lesion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with reduced ejection fraction

Contacts and locations

Locations

  • Kardiopraxis Schirmer

    Kaiserslautern, Germany

  • University of Leipzig

    Leipzig, Saxony, 04103, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.